Title |
Current and future role of biomarkers in Crohn's disease risk assessment and treatment
|
---|---|
Published in |
Clinical and Experimental Gastroenterology, June 2011
|
DOI | 10.2147/ceg.s18187 |
Pubmed ID | |
Authors |
Cyrus P Tamboli, David B Doman, Amar Patel |
Abstract |
Crohn's disease (CD), a chronic inflammatory bowel disease (IBD), occurs in genetically susceptible individuals who develop aberrant immune responses to endoluminal bacteria. Recurrent inflammation increases the risk of several complications. Despite use of a traditional "step-up" therapy with corticosteroids and immunomodulators, most CD patients eventually require surgery at some time in their disease course. Newer biologic agents have been remarkably effective in controlling severe disease. Thus, "top-down," early aggressive therapy has been proposed to yield better outcomes, especially in complicated disease. However, safety and cost issues mandate the need for careful patient selection. Identification of high-risk candidates who may benefit from aggressive therapy is becoming increasingly relevant. Serologic and genetic markers of CD have great potential in this regard. The aim of this review is to highlight the clinical relevance of these markers for diagnostics and prognostication. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
Portugal | 1 | 2% |
Unknown | 60 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 27% |
Other | 9 | 14% |
Student > Ph. D. Student | 8 | 13% |
Student > Master | 6 | 10% |
Student > Bachelor | 4 | 6% |
Other | 14 | 22% |
Unknown | 5 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 46% |
Agricultural and Biological Sciences | 12 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Economics, Econometrics and Finance | 2 | 3% |
Other | 5 | 8% |
Unknown | 7 | 11% |